Lipid Lowering Flashcards

1
Q

What two statins are prodrugs?

A

lovastatin

simvastatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Effect of omega-3 fatty acid supplements on blood lipids

A

decrease TG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Effect of statins on blood lipids

A

reduce LDL

modest reduction in TG and increase in HDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

higher intensity lipid lowering statin

A

atorvastatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

metabolized by CYP3A4

A

atorvastatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

metabolized by sulfating (NOT p450 dependent)

A

pravastatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

except atorvastatin, statins are administered ______ (time of day), when cholesterol biosynthesis takes place

A

QHS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

half life:
atorvastatin _______ hrs
pravastatin ________ hrs

A
14 h (take any time)
2 h (take QHS)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

statin that is excreted unchanged in urine

A

pravastatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

statin that is not protein bound

A

pravastatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

effect of taking food with drug

A

decreased absorption of drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

statin that crosses BBB

A

atorvastatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

well known adverse effect of atorvastatin, when combined with gemfibrozil (inhibits uptake) or drugs that inhibit CYP3A4 (TONS!)

A

myopathy/myalgia

rhabdomyolysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

statin that is hydrophilic and hepatoselective

A

pravastatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

cholesterol absorption blocker at brush border (inhibits Niemann-Pick C1-Like 1)

A

ezetimibe (and its glucuronirated metabolite)

increases expression of LDL-receptor (increased clearance)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

effect of ezetimibe on lipid levels

A

decrease LDL, especially as adjunct

combined with statin - no P450 involvement

17
Q

half life:

ezetimibe

A

22 hours

long due to enterohepatic circulation

18
Q

effect of cholestyramine on lipid levels

A

reduce LDL

modest increase in HDL and TG

19
Q

binds bile acids in the GI –> excretion

A

cholestyramine

up regulates LDL-receptor to increase conversion of cholesterol to bile

20
Q

contraindication to cholestyramine

A

hyperTG

21
Q

give this medication 1 hr after or 2 hrs before other drugs

A

cholestyramine

can bind and impair absorption of other drug

22
Q

effect of niacin on lipid levels

A

increases HDL

lowers TG and LDL

23
Q

inhibits lipolysis in adipose tissue for transport to liver (for VLDL synthesis)

A

niacin (vitamin B3) at high doses

24
Q

contraindications for niacin

A

pregnancy

caution with existing liver and GI issues

25
Q

adverse effect of niacin

A

flushing (declines over 1-2 weeks)

hepatotoxicity (heavy first pass metabolism)

Dyspepsia (huge doses!)

26
Q

effect of fibrates on lipid levels

A

lower TG

27
Q

only fibrate shown to impact outcomes:

A

gemfibrozil

28
Q

gemfibrozil MOA

A

agonist for PPAR-alpha receptor (transcription factor)

essentially - decreases TG synthesis and increases clearance

29
Q

half life gemfibrozil

A

1.1 hours

30
Q

adverse effects of gemfibrozil

A

myopathy
GI discomfort
DRUG interactions due to inhibition of transporter (warfarin, OCP)

31
Q

contraindications for gemfibrozil

A

pregnancy

children

32
Q

best drug for increasing HDL

A

niacin

33
Q

best drug for lowering LDL

A

statins

34
Q

best drug for lowering TG

A

fibrates, niacin, omega-3

only gemfibrozil clinically significant

35
Q

What does PCSK9 do?

A

binds to LDL-R leading to its degradation

36
Q

evolocumab (Repatha)

A

PCSK9 inhibitors

37
Q

problems with evolocumab

A

injected only
expensive
nasopharyngitis

?seem not too efficacious?

38
Q

indication for evolocumab (who gets it?)

A

familial homozygous hypercholesterolemia